ABL Tyrosine Kinase Inhibitors Linked to Arterial Thrombosis – Blood Journals Portfolio
Blood Journals Portfolio shared a post on LinkedIn about a recent article by Richard Travers et al, published in Blood VTH:
”Another important study in observance of Deep Vein Thrombosis Awareness Month, focusing on Arterial Thrombosis.
‘Distinct endothelial cell toxicities of Abl tyrosine kinase inhibitors lead to arterial thrombosis’ published on January 7, 2026, concluded that Dasatinib, ponatinib, and nilotinib damage ECs in different ways, all of which can contribute to arterial thrombosis.”
Title: Distinct endothelial cell toxicities of Abl tyrosine kinase inhibitors lead to arterial thrombosis
Authors: Richard Travers, Alec Stepanian, Sebastiana Redford, Gregory Martin, Nicole L. Svedberg, Kun Xu, Glenn Merrill-Skoloff, Christopher Chen, Robert Flaumenhaft, Iris Z. Jaffe
Read the Full Article on Blood VTH
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 30, 2026, 01:52Javed Anees: DADA2 – When a Young Stroke Is More Than a Stroke
-
Sep 30, 2026, 01:51How a Venous Thrombus Becomes Revascularized – ISTH
-
Sep 29, 2026, 22:45Victor Agunyego: Paracetamol – The Most Common Drug We Underestimate
-
Sep 29, 2026, 22:42Nova Sinclair: Advancing the Future of Hematology – Meet Our 2027 Organizing Committee
-
Sep 29, 2026, 22:41Lorenz Räber: Intracoronary Imaging in PCI – Why, When, How, and Which Modality?
-
Sep 29, 2026, 22:31Selma Turkovic: Pleased to Deliver the Opening Presentation at Kingston Hospital
-
Sep 29, 2026, 22:31Miguel Teran: Ultrasound and Simulation in Arterial Blood Sampling
-
Sep 29, 2026, 22:28Mohammad Refaei: Navigating Your Career in Hematology From Training to Practice
-
Sep 29, 2026, 22:27Matteo Foschi: 10 Clinical Pearls for Antithrombotic Therapy in Secondary Stroke Prevention